RRYVOW in Clinical Studies

Efficacy Endpoints: Pain Freedom

- **Samurai and Spartan 100 mg:** n=544; Difference from placebo=7%;
- **Spartan 50 mg:** n=502; Difference from placebo=8%;
- **Spartan 200 mg:** n=502; Difference from placebo=8%;
- **Spartan 400 mg:** n=502; Difference from placebo=8%.

Sustained Pain Freedom (24 Hrs Post Dose): n=95

- **Samurai and Spartan 100 mg:** n=1049: n=1024; Differences from placebo=32%;
- **Spartan 50 mg:** n=1021; Differences from placebo=31%;
- **Spartan 200 mg:** n=1021; Differences from placebo=31%;
- **Spartan 400 mg:** n=1021; Differences from placebo=31%.

Efficacy Endpoints: Pain Intensity

- **Samurai and Spartan 100 mg:** n=544; Difference from placebo=7%;
- **Spartan 50 mg:** n=502; Difference from placebo=8%;
- **Spartan 200 mg:** n=502; Difference from placebo=8%;
- **Spartan 400 mg:** n=502; Difference from placebo=8%.

Efficacy Endpoints: Pain Relief

- **Samurai and Spartan 100 mg:** n=544; Difference from placebo=7%;
- **Spartan 50 mg:** n=502; Difference from placebo=8%;
- **Spartan 200 mg:** n=502; Difference from placebo=8%;
- **Spartan 400 mg:** n=502; Difference from placebo=8%.

Efficacy Endpoints: Pain Numerical Rating Scale (NRS)

- **Samurai and Spartan 100 mg:** n=544; Difference from placebo=7%;
- **Spartan 50 mg:** n=502; Difference from placebo=8%;
- **Spartan 200 mg:** n=502; Difference from placebo=8%;
- **Spartan 400 mg:** n=502; Difference from placebo=8%.

Efficacy Endpoints: Pain Disability

- **Samurai and Spartan 100 mg:** n=544; Difference from placebo=7%;
- **Spartan 50 mg:** n=502; Difference from placebo=8%;
- **Spartan 200 mg:** n=502; Difference from placebo=8%;
- **Spartan 400 mg:** n=502; Difference from placebo=8%.

Efficacy Endpoints: Activation of 5-HT1F Receptors Has Been Observed in Preclinical Studies: 9, 11, 13

- In general, dizziness was mild or moderate in severity.
- More sleepiness was reported at 8 hours compared to placebo. Advise patients...